ArticleCancer management and research2014
Multiple neoplasms, single primaries, and patient survival.
Article in Cancer management and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 125 citations in OpenAlex.
- Successful Treatment of Synchronous Double Lung and Colon Cancers Using Immune Checkpoint Inhibitors.Internal medicine (Tokyo, Japan) · 2026Article
- WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers.Oncotarget · 2026Article
- Article
- Rising Risk of Subsequent Primary Cancers Among US Cancer Survivors, 2000-2021.Cancer medicine · 2026Article
- Hematological Malignancies With Multiple Primary Cancers: A Rare Case Presentation.Case reports in hematology · 2026Article
- Synchronous Early Gastric Adenocarcinoma and Cervical Carcinoma of Unknown Primary with Metachronous Hepatocellular Carcinoma: A Case Report.OncoTargets and therapy · 2026Article
- Multiple primary malignant neoplasms and long-term survival: A case report.Oncology letters · 2025Article
- Favorable survival of patients with nasopharyngeal carcinoma associated with metachronous multiple primary cancers: A retrospective study.Oncology letters · 2025Article
- Differences of clinical features, prognosis and genetic mutations in Chinese patients with malignant melanoma and additional primary tumours.Annals of medicine · 2025Article
- Multiple Primaries: Differences in Survival of Patients with Glioma with or Without Second Malignancies.Cancers · 2025Article
- Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer.Cancer research communications · 2025Article
- Synchronous/Metachronous Prostate Cancer with Other Cancer Sites-The Experience of a Single Center in Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Hand-Assisted Laparoscopic Rectal Resection-Experience of a Tertiary Oncology Center.Journal of clinical medicine · 2025Article
- Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2025Article
- Risk of Second Primary Neoplasms Among Cancer Survivors: A Population-Based, Cohort Study in Golestan Province, Northern Iran, 2004-2019.Cancer medicine · 2025Article
- Second Primary Malignancies - a Retrospective Analysis from a Regional Cancer Centre of South India.Indian journal of surgical oncology · 2025Article
- Two Simultaneous Primary Cancers: A Case Report.Cureus · 2025Article
- Article
- Castleman disease with synchronous primary rectal and prostate cancers: a case report of successful multimodal treatment and 2-year recurrence-free survival.Frontiers in oncology · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple primary neoplasms in surviving cancer patients are relatively common, with an increasing incidence. Their impact on survival has not been clearly defined.
methodsThis was a retrospective review of clinical data for all consecutive patients with histologically confirmed cancer, with emphasis on single versus multiple primary neoplasms. Second primaries discovered at the workup of the index (first) primary were termed simultaneous, if discovered within 6 months of the index primary were called synchronous, and if discovered after 6 months were termed metachronous.
resultsBetween 2005 and 2012, of 1,873 cancer patients, 322 developed second malignancies; these included two primaries (n=284), and three or more primaries (n=38). Forty-seven patients had synchronous primaries and 275 had metachronous primaries. Patients with multiple primaries were predominantly of Caucasian ancestry (91.0%), with a tendency to develop thrombosis (20.2%), had a strong family history of similar cancer (22.3%), and usually presented with earlier stage 0 through stage II disease (78.9%). When compared with 1,551 patients with a single primary, these figures were 8.9%, 15.6%, 18.3%, and 50.9%, respectively (P≤0.001). Five-year survival rates were higher for metachronous cancers (95%) than for synchronous primaries (59%) and single primaries (59%). The worst survival rate was for simultaneous concomitant multiple primaries, being a median of 1.9 years. The best survival was for patients with three or more primaries (median 10.9 years) and was similar to the expected survival for the age-matched and sex-matched general population (P=0.06991).
conclusionPatients with multiple primaries are usually of Caucasian ancestry, have less aggressive malignancies, present at earlier stages, frequently have a strong family history of similar cancer, and their cancers tend to have indolent clinical behavior with longer survival rates, possibly related to genetic predisposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.